In Depth 9 Aug 2023 Meet the startup working to help treat a rare pediatric cancer …– a central process in the immune system – thereby minimizing pain caused by the antibody binding to peripheral nerves. This, in turn, enables higher antibody dosing. To add to… August 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 Hopes are up: A Second Phase III Trial for Alzheimer’s Disease …returned encouraging data. Biogen’s antibody candidate aducanumab also targets Aβ aggregation and is also currently being evaluated in two large-scale Phase III trials. Even with the recent disappointing results of… February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance …Gilde Healthcare. CatalYm is a Munich-based biotech company, with a novel approach to tackle cancer resistance through its lead candidate, visugromab. This humanized monoclonal antibody targets the tumor-produced growth differentiation… July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 16 Nov 2017 Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics …of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates to control the immune system,… November 16, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2024 Six immunology biotech companies revolutionizing immune treatments in 2024 …mast cells. This candidate will be trialed to treat chronic inducible urticaria. Meanwhile, the company’s second candidate is called SAB03, which agonizes PD-1, a clinically validated target in rheumatoid arthritis,… September 19, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? …antibody targeting PD-L1 and VEGF-A had a 69.7% overall survival rate at 18 months. While the drug overtook Keytruda in the clinic, the question remains of whether the candidate will… January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Oct 2024 Eight nanotechnology companies to watch out for …becomes activated in tumor cells, it is said to work nine times better than radiotherapy alone. The candidate is undergoing a phase 3 trial for head and neck cancer in… October 22, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2023 Beyond insulin: six cutting-edge diabetes biotech companies you should know about …first patient had been enrolled in a phase 1a/b study for its drug candidate ATR-258, which is a first-in-class novel b2 adrenoceptor agonist with a unique mechanism of action for… November 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2020 Artificial Intelligence: A Superpower in the Fight Against Covid-19 …15,000 potential candidates, including approved as well as investigational drugs. All these drug candidates had previously passed the human safety testing stage. The team can rapidly identify treatment candidates, which… July 22, 2020 - 8 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Stramsen Biotech to look at 11 plant-based drug candidates Houston-based biotechnology firm Stramsen Biotech Inc. has announced 11 drug candidates for clinical development. Kefas Mugittu, co-CEO, made the announcement of the plant-based medical candidates. The company said the drugs… June 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2020 Pfizer-BioNTech Covid-19 Vaccine Shows Phase I Promise …different mRNA vaccine candidates against Covid-19 and the interim results come from the most advanced of the four. All of the candidates consist of delivering mRNA molecules into the body… July 3, 2020 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Exeliom Biosciences closes €24M financing for lead candidate …to progress the clinical development of Exeliom Biosciences’ lead candidate, EXL01, into two new therapeutic areas: immuno-oncology and infectious diseases. EXL01 is a once daily, potentially first-in-class, microbiome-based immunotherapy containing… July 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email